Effects Of Urinary Trypsin Inhibitor On The Endotoxemia And SIRS In Patients Undergoing Cardiopulmonary Bypass

Objective: To investigate the effects of urinary trypsin inhibitor on the endotoxemia and SIRS in patients undergoing cardiopulmonary bypass. Methods: In a placebo-controlled clinic trial, 24 patients, who underwent CPB cardiac surgery for the sake of rheumatic heart disease (RHD), were randomized equally into urinary trypsin inhibitor administration group (n=12) and control group (n=12). Blood samples were collected at different time point during perioperative period: before operations (T0), post-anesthesia and before aorta clamping (T1), post-CPB instantly (T2), 4h post-op (T3), 8h post-op (T4), 24h post-op (T5), 48h post-op (T6), 72h post-op (T7) respectively. The concentrations of plasmic endotoxin were assessed by BET-24A endotoxin-detector. The concentrations of TNF-α, IL-1β, IL-6 and IL-8 in the blood of the patients were detected by radio-immunoassay. All patients'general organ function were examined. Results: There was no significant effect of urinary trypsin inhibitor on the endotoxemia post-CPB. The concentrations of TNF-α, IL-1β, IL-6, and IL-8 in the patients using UTI were significantly lower than that in the control group. Conclusion: UTI can inhibit the post-CPB elevation of proinflammatory cytokines, thus improves the postoperative recovery, but have no effect on the post-CPB endotoxemia.